Discoidin domain receptors orchestrate cancer progression: A focus on cancer therapies

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Discoidin domain receptors (DDR), including DDR1 and DDR2, are transmembrane receptor tyrosine kinases activated by collagen.
• DDR signaling regulates critical cellular processes like proliferation, migration, and apoptosis, impacting physiological and pathological conditions.
• Aberrant DDR expression is implicated in various human cancers, highlighting their potential as therapeutic targets.

Purpose of the Study:

• To review the literature on the role of DDR in cancer progression.
• To summarize the development status of DDR inhibitors.
• To discuss the clinical potential of targeting DDR in cancer therapies.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of studies on DDR function in cancer.
• Evaluation of pre-clinical data for DDR inhibitors.

Main Results:

• DDRs play a significant role in cancer progression through regulating cell-collagen interactions.
• Several DDR inhibitors have demonstrated therapeutic efficacy in pre-clinical cancer models.
• Aberrant DDR expression is a common feature in human cancers.

Conclusions:

• DDR1 and DDR2 represent promising therapeutic targets for cancer treatment.
• The development of DDR inhibitors is advancing, with potential for clinical application.
• Targeting DDR signaling pathways offers a novel strategy for anti-cancer therapies.